Published in Am J Pathol on May 01, 2007
Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA (2011) 7.10
The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med (2008) 3.31
Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med (2008) 2.93
The pathogenesis of sepsis. Annu Rev Pathol (2011) 2.55
Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit Care Med (2009) 2.04
IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol (2009) 1.91
Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun (2010) 1.76
Impact of interleukin-10, soluble CD25 and interferon-γ on the prognosis and early diagnosis of bacteremic systemic inflammatory response syndrome: a prospective observational study. Crit Care (2013) 1.39
Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics (2011) 1.38
Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit Care (2011) 1.38
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood (2009) 1.36
A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J Immunol (2011) 1.36
A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med (2011) 1.28
Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology (2011) 1.21
Pathophysiologic mechanisms in septic shock. Lab Invest (2013) 1.19
Peroxisome proliferator-activated receptor {delta} regulates inflammation via NF-{kappa}B signaling in polymicrobial sepsis. Am J Pathol (2010) 1.19
Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis (2012) 1.10
Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Crit Care (2010) 1.08
Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int J Mol Sci (2009) 1.08
Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue. PLoS One (2010) 1.08
TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood (2013) 1.06
Hospital readmission and healthcare utilization following sepsis in community settings. J Hosp Med (2014) 1.06
Actinonin, a meprin A inhibitor, protects the renal microcirculation during sepsis. Shock (2011) 1.05
Novel regulators of the systemic response to lipopolysaccharide. Am J Respir Cell Mol Biol (2010) 1.04
The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis. PLoS One (2008) 1.03
Blood glucose control in patients with severe sepsis and septic shock. World J Gastroenterol (2009) 1.01
Presence of preexisting antibodies mediates survival in sepsis. Shock (2012) 1.01
MicroRNA 21 (miR-21) and miR-181b couple with NFI-A to generate myeloid-derived suppressor cells and promote immunosuppression in late sepsis. Infect Immun (2014) 1.00
Hydrogen sulfide and neurogenic inflammation in polymicrobial sepsis: involvement of substance P and ERK-NF-κB signaling. PLoS One (2011) 0.99
Surface-micromachined microfiltration membranes for efficient isolation and functional immunophenotyping of subpopulations of immune cells. Adv Healthc Mater (2013) 0.97
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). Crit Care (2008) 0.97
Clinical review: flow cytometry perspectives in the ICU - from diagnosis of infection to monitoring of injury-induced immune dysfunctions. Crit Care (2011) 0.97
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care (2013) 0.96
Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice. J Immunol (2014) 0.96
Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice. Shock (2011) 0.96
Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical Sepsis. PLoS One (2016) 0.94
Human ghrelin ameliorates organ injury and improves survival after radiation injury combined with severe sepsis. Mol Med (2009) 0.93
Attenuated response of aged mice to respiratory Francisella novicida is characterized by reduced cell death and absence of subsequent hypercytokinemia. PLoS One (2010) 0.93
Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury. Pharmacol Ther (2012) 0.93
Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock? Crit Care (2015) 0.93
Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis. Infect Immun (2011) 0.93
New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study. Crit Care (2014) 0.91
High-mobility group box 1 mediates persistent splenocyte priming in sepsis survivors: evidence from a murine model. Shock (2013) 0.91
Role of plasma matrix-metalloproteases (MMPs) and their polymorphisms (SNPs) in sepsis development and outcome in ICU patients. Sci Rep (2014) 0.90
Reversing established sepsis in rats with human vasoactive hormone adrenomedullin and its binding protein. Mol Med (2008) 0.90
The role of the mitochondrial glycine cleavage complex in the metabolism and virulence of the protozoan parasite Leishmania major. J Biol Chem (2007) 0.90
Mechanical ventilation during experimental sepsis increases deposition of advanced glycation end products and myocardial inflammation. Crit Care (2009) 0.89
Effect of high-dose Ascorbic acid on vasopressor's requirement in septic shock. J Res Pharm Pract (2016) 0.89
Upregulation of GRAIL is associated with impaired CD4 T cell proliferation in sepsis. J Immunol (2014) 0.88
Failed interleukin-6 signal transduction in murine sepsis: attenuation of hepatic glycoprotein 130 phosphorylation. Crit Care Med (2009) 0.88
Milk fat globule EGF factor 8 attenuates sepsis-induced apoptosis and organ injury in alcohol-intoxicated rats. Alcohol Clin Exp Res (2010) 0.88
Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis. PLoS One (2012) 0.88
Ensemble models of neutrophil trafficking in severe sepsis. PLoS Comput Biol (2012) 0.87
Protein kinase G oxidation is a major cause of injury during sepsis. Proc Natl Acad Sci U S A (2013) 0.87
Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother (2012) 0.87
Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study. Clin Exp Immunol (2011) 0.87
LPS pretreatment ameliorates multiple organ injuries and improves survival in a murine model of polymicrobial sepsis. Inflamm Res (2011) 0.87
Granzyme K synergistically potentiates LPS-induced cytokine responses in human monocytes. Proc Natl Acad Sci U S A (2014) 0.86
An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy. Virulence (2013) 0.86
Period of irreversible therapeutic intervention during sepsis correlates with phase of innate immune dysfunction. J Biol Chem (2012) 0.86
Mitochondrial N-formyl peptides induce cardiovascular collapse and sepsis-like syndrome. Am J Physiol Heart Circ Physiol (2015) 0.86
PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. Br J Pharmacol (2011) 0.85
MicroRNA-146a and RBM4 form a negative feed-forward loop that disrupts cytokine mRNA translation following TLR4 responses in human THP-1 monocytes. Immunol Cell Biol (2013) 0.85
Pathophysiology, staging and therapy of severe sepsis in baboon models. J Cell Mol Med (2012) 0.84
Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study. Multidiscip Respir Med (2013) 0.84
The role of immunostimulatory nucleic acids in septic shock. Int J Clin Exp Med (2012) 0.84
NFI-A disrupts myeloid cell differentiation and maturation in septic mice. J Leukoc Biol (2015) 0.83
Enhanced survival from CLP-induced sepsis following late administration of low doses of anti-IFNγ F(ab')2 antibody fragments. Inflamm Res (2011) 0.83
In vitro model of sepsis-induced renal epithelial reactive nitrogen species generation. Toxicol Sci (2010) 0.83
Mitogen-activated protein kinase phosphatase 1 disrupts proinflammatory protein synthesis in endotoxin-adapted monocytes. Clin Vaccine Immunol (2013) 0.83
Microfluidic amperometric sensor for analysis of nitric oxide in whole blood. Anal Chem (2013) 0.83
TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen. BMC Infect Dis (2011) 0.83
Effect of carbon monoxide-releasing molecules II-liberated CO on suppressing inflammatory response in sepsis by interfering with nuclear factor kappa B activation. PLoS One (2013) 0.83
Formal modelling of toll like receptor 4 and JAK/STAT signalling pathways: insight into the roles of SOCS-1, interferon-β and proinflammatory cytokines in sepsis. PLoS One (2014) 0.82
The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clin Exp Immunol (2015) 0.82
Disturbances of the hypothalamic-pituitary-adrenal axis and plasma electrolytes during experimental sepsis. Ann Intensive Care (2011) 0.81
Substance P in polymicrobial sepsis: molecular fingerprint of lung injury in preprotachykinin-A-/- mice. Mol Med (2010) 0.81
What is old is new again: acetaminophen as a novel approach to treating sepsis. Crit Care Med (2015) 0.81
Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model. Clin Vaccine Immunol (2011) 0.80
Peritoneal wash contents used to predict mortality in a murine sepsis model. J Surg Res (2015) 0.80
Bench to bedside: A role for erythropoietin in sepsis. Crit Care (2010) 0.79
Adoptive transfer of bone marrow-derived dendritic cells decreases inhibitory and regulatory T-cell differentiation and improves survival in murine polymicrobial sepsis. Immunology (2015) 0.79
Differential expression of CD14-dependent and independent pathways for chemokine induction regulates neutrophil trafficking in infection. J Leukoc Biol (2012) 0.79
NK cell intrinsic regulation of MIP-1α by granzyme M. Cell Death Dis (2014) 0.79
Platelet secretion of CXCL4 is Rac1-dependent and regulates neutrophil infiltration and tissue damage in septic lung damage. Br J Pharmacol (2015) 0.79
Genetic deletion of the HIF-1α isoform I.1 in T cells enhances antibacterial immunity and improves survival in a murine peritonitis model. Eur J Immunol (2013) 0.79
Metalloproteinases regulate CD40L shedding from platelets and pulmonary recruitment of neutrophils in abdominal sepsis. Inflamm Res (2012) 0.79
Therapeutic interventions in sepsis: current and anticipated pharmacological agents. Br J Pharmacol (2014) 0.78
IL-15 Superagonist Expands mCD8+ T, NK and NKT Cells after Burn Injury but Fails to Improve Outcome during Burn Wound Infection. PLoS One (2016) 0.78
Cystathionine-Gamma-Lyase Gene Deletion Protects Mice against Inflammation and Liver Sieve Injury following Polymicrobial Sepsis. PLoS One (2016) 0.77
Diagnosing sepsis: does the microbiology matter? Crit Care (2008) 0.77
Diagnostic and prognostic utility of tissue factor for severe sepsis and sepsis-induced acute lung injury. J Transl Med (2015) 0.77
Effects of Rhubarb combined with ulinastatin on T-cell subsets in sepsis rats. Int J Clin Exp Med (2015) 0.77
The lysis of pathogenic Escherichia coli by bacteriophages releases less endotoxin than betalactams. Clin Infect Dis (2017) 0.77
Astragaloside IV inhibits NF- κ B activation and inflammatory gene expression in LPS-treated mice. Mediators Inflamm (2015) 0.77
Improved antimicrobial host defense in mice following poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose glucan treatment by a gender-dependent immune mechanism. Clin Vaccine Immunol (2011) 0.77
Comparative Assessment of Cytokine Pattern in Early and Late Onset of Neonatal Sepsis. J Immunol Res (2017) 0.77
Eritoran: the evidence of its therapeutic potential in sepsis. Core Evid (2008) 0.76
Processing Body Formation Limits Proinflammatory Cytokine Synthesis in Endotoxin-Tolerant Monocytes and Murine Septic Macrophages. J Innate Immun (2015) 0.76
Suppressive effect of CORM-2 on LPS-induced platelet activation by glycoprotein mediated HS1 phosphorylation interference. PLoS One (2013) 0.76
Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med (2001) 51.99
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med (2001) 46.58
Intensive insulin therapy in critically ill patients. N Engl J Med (2001) 40.00
The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med (2003) 32.30
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 28.68
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (1985) 19.41
HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 17.72
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA (2002) 16.37
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
Tissue destruction by neutrophils. N Engl J Med (1989) 13.81
Management of sepsis. N Engl J Med (2006) 9.01
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med (2005) 8.55
Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 7.24
Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med (1999) 7.24
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med (1996) 5.25
Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med (1997) 5.19
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol. Crit Care Med (2006) 4.62
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet (1998) 4.05
Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol (2006) 3.75
Neutrophils in development of multiple organ failure in sepsis. Lancet (2006) 3.64
Animal models of sepsis: setting the stage. Nat Rev Drug Discov (2005) 3.63
Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med (1996) 3.61
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med (2004) 3.61
Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock (2000) 3.12
Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock (2002) 3.10
Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol (1994) 3.03
The interactions between inflammation and coagulation. Br J Haematol (2005) 2.92
Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med (1993) 2.84
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med (1994) 2.66
How does blood glucose control with insulin save lives in intensive care? J Clin Invest (2004) 2.65
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med (2001) 2.56
Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol (2005) 2.47
Leukocyte apoptosis and its significance in sepsis and shock. J Leukoc Biol (2005) 2.38
Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg (1995) 2.38
Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med (2006) 2.32
Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med (2000) 2.26
Evaluation of an intensive insulin protocol for septic patients in a medical intensive care unit. Crit Care Med (2006) 2.22
Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest (2005) 2.11
Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest (1987) 2.06
Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med (2003) 1.98
Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost (2006) 1.98
Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov (2003) 1.92
Delayed neutrophil apoptosis in sepsis is associated with maintenance of mitochondrial transmembrane potential and reduced caspase-9 activity. Crit Care Med (2004) 1.90
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med (2001) 1.88
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med (1996) 1.87
Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J (2001) 1.73
INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med (1996) 1.73
Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol (2000) 1.72
Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci U S A (2003) 1.71
Lower levels of whole blood LPS-stimulated cytokine release are associated with poorer clinical outcomes in surgical ICU patients. Surg Infect (Larchmt) (2003) 1.69
Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial. Crit Care Med (1998) 1.65
Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clin (2001) 1.58
Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med (2005) 1.53
Inflammatory status in sepsis alters efficacy of interleukin-18 binding protein therapy. Crit Care Med (2003) 1.48
Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des (2003) 1.42
Development of a sensitive microarray immunoassay and comparison with standard enzyme-linked immunoassay for cytokine analysis. Shock (2004) 1.36
Molecular mechanisms of bacteria induced apoptosis. Apoptosis (2001) 1.36
Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock (2003) 1.35
The systemic inflammatory response syndrome. Microbes Infect (2006) 1.31
An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med (2005) 1.29
Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infect Immun (2006) 1.20
Neutrophil chemotaxis and receptor expression in clinical septic shock. Intensive Care Med (2004) 1.17
Endotoxin and tumour necrosis factor do not cause mortality from caecal ligation and puncture. Cytokine (1994) 1.16
Role of apoptosis in Pseudomonas aeruginosa pneumonia. Science (2001) 1.11
Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med (2006) 1.11
Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med (2004) 1.10
Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch Surg (1994) 1.06
Pathobiology of sepsis: are we still asking the same questions? Am J Respir Cell Mol Biol (2006) 1.03
Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Arch Surg (2006) 1.02
Enhanced neutrophil migratory activity following major blunt trauma. Injury (2005) 1.01
Early trauma polymorphonuclear neutrophil responses to chemokines are associated with development of sepsis, pneumonia, and organ failure. J Trauma (2001) 0.98
Adjunctive therapies in sepsis: an evidence-based review. Crit Care Med (2004) 0.95
Impaired ex vivo lipopolysaccharide-stimulated whole blood tumor necrosis factor production may identify "septic" intensive care unit patients. Shock (2000) 0.94
CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med (1995) 0.90
Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg (1995) 0.87
Protein C, isolation and potential use in prevention of thrombosis. Dev Biol Stand (1987) 0.82
Defective IL-2 production in patients with severe burns and sepsis. Lymphokine Res (1986) 0.80